BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKesson
Fish and Richardson
Cerilliant
Chubb
Healthtrust
Moodys
US Army
Express Scripts
Baxter

Generated: January 16, 2018

DrugPatentWatch Database Preview

LUMIGAN Drug Profile

« Back to Dashboard

When do Lumigan patents expire, and when can generic versions of Lumigan launch?

Lumigan is a drug marketed by Allergan and is included in two NDAs. There are twelve patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-three patent family members in twenty-one countries and three supplementary protection certificates in three countries.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for LUMIGAN
International Patents:33
US Patents:12
Applicants:1
NDAs:2
Suppliers / Packagers: 2
Bulk Api Vendors: 42
Clinical Trials: 36
Patent Applications: 1,807
Drug Prices:see details
DailyMed Link:LUMIGAN at DailyMed
Drug patent expirations by year for LUMIGAN
Pharmacology for LUMIGAN
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for LUMIGAN

US Patents and Regulatory Information for LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LUMIGAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 4/5/2011
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 12/22/2008

International Patents for LUMIGAN

Supplementary Protection Certificates for LUMIGAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0033 France ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
00099 Netherlands ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C/GB02/035 United Kingdom ➤ Subscribe PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
UBS
McKinsey
Argus Health
AstraZeneca
Express Scripts
Chubb
Federal Trade Commission
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot